Tectonic Therapeutic (TECX) Net Income towards Common Stockholders (2017 - 2026)

Tectonic Therapeutic (TECX) has reported Net Income towards Common Stockholders for 10 consecutive years, with -$25.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 58.69% year-over-year to -$25.2 million; the TTM figure through Mar 2026 stood at -$83.5 million (down 42.3% YoY), while the FY2025 annual figure was -$74.2 million, down 27.89% from the prior year.
• Net Income towards Common Stockholders eased to -$25.2 million in Q1 2026 per TECX's latest filing, from -$19.2 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $67.5 million in Q2 2023 and bottomed at -$31.1 million in Q1 2022.
• Historically, Net Income towards Common Stockholders has averaged -$14.2 million across 5 years, with a median of -$19.0 million in 2025.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 340.52% — and 2024, when it tumbled 118.78%.
• Tectonic Therapeutic's Net Income towards Common Stockholders stood at -$25.0 million in 2022, then surged by 68.57% to -$7.9 million in 2023, then slumped by 57.24% to -$12.4 million in 2024, then tumbled by 55.39% to -$19.2 million in 2025, then slumped by 31.29% to -$25.2 million in 2026.
• Business Quant data shows TECX's Net Income towards Common Stockholders at -$25.2 million in Q1 2026, -$19.2 million in Q4 2025, and -$19.0 million in Q3 2025.